- Home
- DAC vs IMCR Comparison
DAC vs IMCR Comparison
Compare DAC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAC
- IMCR
- Stock Information
- Founded
- DAC 1972
- IMCR 2008
- Country
- DAC Greece
- IMCR United Kingdom
- Employees
- DAC N/A
- IMCR N/A
- Industry
- DAC Marine Transportation
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DAC Consumer Discretionary
- IMCR Health Care
- Exchange
- DAC Nasdaq
- IMCR Nasdaq
- Market Cap
- DAC 1.6B
- IMCR 1.5B
- IPO Year
- DAC 2006
- IMCR 2021
- Fundamental
- Price
- DAC $87.29
- IMCR $31.34
- Analyst Decision
- DAC Strong Buy
- IMCR Buy
- Analyst Count
- DAC 1
- IMCR 10
- Target Price
- DAC $105.00
- IMCR $58.13
- AVG Volume (30 Days)
- DAC 98.1K
- IMCR 560.7K
- Earning Date
- DAC 08-04-2025
- IMCR 08-07-2025
- Dividend Yield
- DAC 3.92%
- IMCR N/A
- EPS Growth
- DAC N/A
- IMCR N/A
- EPS
- DAC 24.48
- IMCR N/A
- Revenue
- DAC $1,013,968,000.00
- IMCR $333,581,000.00
- Revenue This Year
- DAC $2.55
- IMCR $26.82
- Revenue Next Year
- DAC N/A
- IMCR $8.15
- P/E Ratio
- DAC $3.58
- IMCR N/A
- Revenue Growth
- DAC 3.10
- IMCR 25.75
- 52 Week Low
- DAC $65.40
- IMCR $23.15
- 52 Week High
- DAC $94.63
- IMCR $41.54
- Technical
- Relative Strength Index (RSI)
- DAC 56.87
- IMCR 40.28
- Support Level
- DAC $85.48
- IMCR $35.10
- Resistance Level
- DAC $88.29
- IMCR $37.56
- Average True Range (ATR)
- DAC 2.06
- IMCR 1.74
- MACD
- DAC -0.02
- IMCR -0.79
- Stochastic Oscillator
- DAC 59.59
- IMCR 0.75
About DAC Danaos Corporation
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.